429 related articles for article (PubMed ID: 31281165)
41. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
Gill S; June CH
Immunol Rev; 2015 Jan; 263(1):68-89. PubMed ID: 25510272
[TBL] [Abstract][Full Text] [Related]
42. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
[TBL] [Abstract][Full Text] [Related]
43. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
44. [Target and Manufacturing of Chimeric Antigen Receptor T cells for T-cell Malignancies--Review].
Yuan L; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):288-292. PubMed ID: 33554836
[TBL] [Abstract][Full Text] [Related]
45. [CAR T-cell therapy: Balance of efficacy and safety].
Kulemzin SV; Kuznetsova VV; Mamonkin M; Taranin AV; Gorchakov AA
Mol Biol (Mosk); 2017; 51(2):274-287. PubMed ID: 28537234
[TBL] [Abstract][Full Text] [Related]
46. [Cell therapy in all its forms].
Dougé A; Caux C; Bay JO
Bull Cancer; 2024 Feb; 111(2):213-221. PubMed ID: 38242769
[TBL] [Abstract][Full Text] [Related]
47. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
48. Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.
Ghosh A; Politikos I; Perales MA
Curr Opin Oncol; 2017 Nov; 29(6):474-483. PubMed ID: 28872470
[TBL] [Abstract][Full Text] [Related]
49. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy.
Bouziana S; Bouzianas D
Crit Rev Oncol Hematol; 2021 Jan; 157():103096. PubMed ID: 33181441
[TBL] [Abstract][Full Text] [Related]
50. Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials.
Ormhøj M; Abken H; Hadrup SR
Cancer Immunol Immunother; 2022 Oct; 71(10):2301-2311. PubMed ID: 35199207
[TBL] [Abstract][Full Text] [Related]
51. Implications of T cell receptor biology on the development of new T cell therapies for cancer.
Hardy IR; Schamel WW; Baeuerle PA; Getts DR; Hofmeister R
Immunotherapy; 2020 Jan; 12(1):89-103. PubMed ID: 31902264
[TBL] [Abstract][Full Text] [Related]
52. Chimeric antigen receptor T cell treatment in hematologic malignancies.
Goker H; Malkan UY; Demiroglu H; Buyukasik Y
Transfus Apher Sci; 2016 Feb; 54(1):35-40. PubMed ID: 26874466
[TBL] [Abstract][Full Text] [Related]
53. T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments.
Azizi AA; Pillai M; Thistlethwaite FC
Curr Opin Oncol; 2019 Sep; 31(5):430-438. PubMed ID: 31335828
[TBL] [Abstract][Full Text] [Related]
54. [Cancer Immunotherapy Using Gene Modification Technology].
Tokunaga Y; Tamada K
Gan To Kagaku Ryoho; 2019 Jun; 46(6):967-973. PubMed ID: 31273158
[TBL] [Abstract][Full Text] [Related]
55. The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.
Nagle SJ; Garfall AL; Stadtmauer EA
Cancer J; 2016; 22(1):27-33. PubMed ID: 26841014
[TBL] [Abstract][Full Text] [Related]
56. [Advances in immunotherapy of hematological malignancies by using chimeric antigen receptor-modified lymphocytes].
Xu XJ; Zhao HZ; Tang YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):521-5. PubMed ID: 23628068
[TBL] [Abstract][Full Text] [Related]
57. Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.
Perales MA; Sauter CS; Armand P
Biol Blood Marrow Transplant; 2016 Jan; 22(1):17-22. PubMed ID: 26485445
[TBL] [Abstract][Full Text] [Related]
58. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
[TBL] [Abstract][Full Text] [Related]
59. Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.
Xu J; Tian K; Zhang H; Li L; Liu H; Liu J; Zhang Q; Zheng J
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1099-1106. PubMed ID: 29048935
[TBL] [Abstract][Full Text] [Related]
60. [Chimeric antigen receptor T cells for hematological malignancies: current understanding and future challenge].
Yan ZL; Li ZY; Xu KL
Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):793-795. PubMed ID: 31665852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
